Date — Nov 18
2:30 pm - 7:00 pm
The Nippon Club
Part 1: “Most Urgent Policy Issues Facing the Biopharma Industry” (2:30 – 4:15 pm)
Numerous American organizations are devoted to researching and reporting on the many healthcare policy issues facing the U.S. There’s a lot to read and keep track of in this area. Some of these same issues also face Japan and other countries. In the fast-changing healthcare environment, it’s hard for the average pharma industry executive to know which issues will have the most impact on their companies’ operations and profitability.
At this upcoming program, two experts devoted to analyzing these issues will discuss 10 different issues they believe are most urgent and will have the biggest impact on pharma. Michael McCaughan has spoken in the past at a NYPF meeting when he was editor-in-chief, Elsevier Business Intelligence (which included several different trade magazines such as Pink Sheet and In Vivo). He is currently editor of the RPM report and is a founding member of policy consulting firm Prevision Policy. Prior to joining PhRMA, Lori Reilly was Counsel at the U.S. House of Representatives Committee on Commerce, and earlier was Chief of Staff/Counsel to Rep. Jon Christensen, a member of the House Ways and Means Committee.
Speakers will be:
- Michael McCaughan, Editor, The RPM Report, and Founding Member, Prevision Policy LLC; former editor-in-chief at Elsevier Business Intelligence
- Lori Reilly, Vice President for Policy & Research, Pharmaceutical Research & Manufacturers Association (PhRMA)
Part 2: “The Twin Epidemics of Obesity and Diabetes” (4:30-5:45 pm)
The World Health Organization has declared epidemics of obesity and diabetes worldwide. Over 23 million Americans have diabetes, and those who are overweight have a much higher risk of developing type 2 diabetes than normal weight people. While only 3.2% of Japan’s population is obese (the lowest obesity rate in the world), the U.S. obesity rate is over 30%. A year ago, the American Medical Association officially declared obesity a disease. While there are hundreds of drugs for diabetes, for obesity only four drugs are FDA-approved. Three were approved in the last six months, but prior to that, no obesity drugs were approved for 13 years. Speakers at this program will discuss why the FDA has approved so few obesity drugs, obesity and diabetes drug approval considerations, off-label drugs obesity specialists are using (including diabetes drugs), common usage of “drug cocktails” for obesity, research efforts in obesity and diabetes that seem the most promising and difficulties faced by both obesity patients –especially those with diabetes – and obesity physician specialists.
Dr. Aronne, as a practicing obesity specialist, sees this twin epidemic close up every day and is very involved in clinical research on new obesity treatments. Ms. Choe is a former Team Leader at the FDA with both obesity and diabetes drug review responsibilities. Prior to the FDA, she held positions with Pfizer and Bristol-Myers Squibb.
Speakers will be:
- Louis J. Aronne, MD, FACP, the Sanford I. Weill Professor of Metabolic Research at Weill-Cornell Medical College and director of the Center for Weight Management and Metabolic Clinical Research, an obesity research and treatment program; past president of the Obesity Society.
- Sally Choe, Ph.D., senior director, Parexel; formerly team leader at the FDA with both obesity and diabetes drug review responsibilities. Prior to the FDA, she was with Pfizer and Bristol-Myers Squibb.